BioRestorative Therapies (BioRestorative Therapies) Earnings per Share (Diluted) : $-3.51 (TTM As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is BioRestorative Therapies Earnings per Share (Diluted)?

BioRestorative Therapies's Earnings per Share (Diluted) for the three months ended in Dec. 2023 was $-0.57. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-3.51.

BioRestorative Therapies's EPS (Basic) for the three months ended in Dec. 2023 was $-0.57. Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2023 was $-3.51.

BioRestorative Therapies's EPS without NRI for the three months ended in Dec. 2023 was $-0.57. Its EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2023 was $-3.51.

During the past 3 years, the average EPS without NRIGrowth Rate was 21.50% per year. During the past 5 years, the average EPS without NRI Growth Rate was 75.30% per year. During the past 10 years, the average EPS without NRI Growth Rate was 9.90% per year.

During the past 13 years, BioRestorative Therapies's highest 3-Year average EPS without NRI Growth Rate was 89.60% per year. The lowest was -1024.70% per year. And the median was 30.70% per year.

BioRestorative Therapies Earnings per Share (Diluted) Historical Data

The historical data trend for BioRestorative Therapies's Earnings per Share (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioRestorative Therapies Earnings per Share (Diluted) Chart

BioRestorative Therapies Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Earnings per Share (Diluted)

Get a 7-Day Free Trial

-752.64

-15.75

-37.30

-5.11

-3.42

BioRestorative Therapies Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Earnings per Share (Diluted)	Get a 7-Day Free Trial															-1.18	-1.53	-0.77	-0.64	-0.57

Competitive Comparison of BioRestorative Therapies's Earnings per Share (Diluted)

For the Biotechnology subindustry, BioRestorative Therapies's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

BioRestorative Therapies's PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BioRestorative Therapies's PE Ratio distribution charts can be found below:

* The bar in red indicates where BioRestorative Therapies's PE Ratio falls into.

BioRestorative Therapies Earnings per Share (Diluted) Calculation

Earnings Per Share (EPS) is the amount of earnings per outstanding share of the company's stock. In calculating earnings per share, the dividends of preferred stocks need to subtracted from the total net income first.

BioRestorative Therapies's Earnings Per Share (Diluted) for the fiscal year that ended in Dec. 2023 is calculated as

Diluted Earnings Per Share (A: Dec. 2023 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Diluted Average)
	=	(-14.415	-	0)	/	4.218
	=	-3.42

BioRestorative Therapies's Earnings Per Share (Diluted) for the quarter that ended in Dec. 2023 is calculated as

Diluted Earnings Per Share (Q: Dec. 2023 )	=	(Net Income	-	Preferred Dividends	/	Shares Outstanding (Diluted Average)
	=	(-2.825	-	0)	/	4.687
	=	-0.60

Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-3.51

Companies also reported diluted shares in their financial reports. Diluted shares include the shares of convertibles or warrants outstanding.

BioRestorative Therapies (NAS:BRTX) Earnings per Share (Diluted) Explanation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

BioRestorative Therapies Earnings per Share (Diluted) Related Terms

Thank you for viewing the detailed overview of BioRestorative Therapies's Earnings per Share (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.

BioRestorative Therapies (BioRestorative Therapies) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioRestorative Therapies Inc (NAS:BRTX) » Definitions » Earnings per Share (Diluted)

Comparable Companies

Traded in Other Exchanges

9OF:Germany

Address

40 Marcus Drive, Suite One, Melville, NY, USA, 11747

Website

https://www.biorestorative.com

BioRestorative Therapies Inc is a biotechnology company based in the United States. It focuses on the development of regenerative medicine products and therapies using cell and tissue protocols, primarily involving adult (non-embryonic) stem cells. The company's two core development programs include the Disc/Spine Program, which involves cell therapy candidate, BRTX-100, a product formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow; and Metabolic Program, which includes the development of cell-based therapy to target obesity and metabolic disorders using brown adipose-derived stem cells, to generate brown adipose tissue.

Executives

Dale Broadrick	10 percent owner	3003 BRICK CHURCH PIKE, NASHVILLE TN 37207
Lance Alstodt	director, 10 percent owner, officer: President, CEO, COB	BIORESTORATIVE THERAPIES, INC., 40 MARCUS DRIVE, SUITE 1, MELVILLE NY 11747
Francisco Silva	director, 10 percent owner, officer: VP of Research and Development	STEM CELL ASSURANCE, INC., 555 HERITAGE DRIVE, JUPITER FL 33458
Robert Eugene Kristal	officer: Chief Financial Officer	4719 COLE AVENUE, DALLAS TX 75205
Patrick F. Williams	director	C/O ZELTIQ AESTHETICS INC., 4698 WILLOW ROAD, SUITE 100, PLEASANTON CA 94588
David A Rosa	director	10901 RED CIRCLE DRIVE, SUITE 150, MINNETONKA MN 55343
Nickolay V. Kukekov	director	4524 WESTWAY AVE, DALLAS TX 75205
Mark Weinreb	director, 10 percent owner, officer: CEO and Chairman of the Board	STEM CELL ASSURANCE, INC., 555 HERITAGE DRIVE, JUPITER FL 33458
Paul Jude Tonna	director	69 CHICHESTER ROAD, HUNTINGTON NY 11743
A. Jeffrey Radov	director	8 WALWORTH AVENUE, SCARSDALE NY 10583
Robert Paccasassi	officer: VP, Quality and Compliance	C/O BIORESTORATIVE THERAPIES, INC., 40 MARCUS DRIVE, SUITE 1, MELVILLE NY 11747
Robert B Catell	director	62 OSBORNE ROAD, GARDEN CITY NY 11530
Adam D. Bergstein	officer: SVP, Planning and Business Dev	167 HAZEL AVENUE, GLENCOE IL 60022
John M Desmarais	director	230 PARK AVENUE, NEW YORK NY 10169
Westbury Trust	10 percent owner	VICTORIA HALL, 11 VICTORIA STREET, P.O. BOX HM 1065, HAMILTON D0 00000